Amiodarone monitoring: are existing guidelines outdated? In this interview, A. John Camm, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Tiffany Y. Hu, MD, discuss Amiodarone monitoring in 2021.   Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Amiodarone Monitoring in 2021

As the number of women of childbearing age with heart disease grows, the importance of safe and effective birth control counseling for pregnancy planning is more important than ever. Which contraceptive methods are optimal for women with cardiovascular disease? In this interview, Kathryn J. Lindley, MD, FACC and Laxmi Mehta MD, FACC, with Lindsay Panah, MD, discuss Contraception and Reproductive Planning for Women with Cardiovascular Disease. Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

ACCEL Lite: Contraception and Reproductive Planning for Women with Cardiovascular Disease

This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. In this interview, Bertram Pitt, MD and Michelle L. O’Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes. Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations. In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients. Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL

ACCEL Lite: ESC Late Breaker: MASTER DAPT

In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and hospitalisation for patients with heart failure and a preserved fraction with and without diabetes. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: ESC Congress 2021 Late Breaker: EMPEROR-Preserved

In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial

In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the risk of the primary composite endpoint of all-cause death, MI, and stent thrombosis. Influenza vaccine also reduced two of the three key secondary endpoints. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: ESC Congress 2021 Late Breaker: IAMI

In this interview, Michelle Kittleson, MD, FACC, and Steffen Desch, MD, discuss the ESC Congress late-breaker TOMAHAWK, which examined whether immediate coronary angiography in survivors of out-of-hospital cardiac arrest and no ST-segment elevation is beneficial with regard to all-cause mortality at 30 days, compared with initial intensive care assessment with delayed/selective angiography. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: ESC Congress 2021 Late-Breaker: TOMAHAWK

In this interview, Andrea Russo, MD, FACC; Marek Jastrzebski, MD, PhD; and Jeffrey Hsu, MD, PhD, focus on a Heart Rhythm Society late-breaking study on LBB optimized CRT, discussing its differences from traditional pacing and benefits to the patient, limitations of the alternative techniques, and a new method to more fully restore physiology of depolarization of the LV in patients with HF and broad QRS complex. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: HRS Late Breaker: LBB-Optimized CRT

Geriatric principles impact the utility, performance, and interpretation of CV imaging tests. Considering geriatric principles can improve the patient experience during CV testing and the application of test results to clinical care. In this interview, Jeroen Bax, PhD, MD, FACC; Jim Kirkpatrick, MD, FACC; and Akhil Narang, MD, FACC, discuss the clinical utility and age-related challenges of CV imaging in older patients. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Clinical Utility and Age-Related Challenges of CV Imaging in Older Patients

Should we deprescribe statins after age 75, or could this commonly used heart medication benefit other conditions of aging? How does cognitive function relate to vascular health, and could statins be useful? In this interview, Annabelle Volgman, MD, FACC; Karen Alexander, MD; and Taimur Safder, MD, MPH, discuss primary prevention and statins in adults over the age of 75 and the PREVENTABLE study, now enrolling. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Primary Prevention and Statins in Adults Over Age 75

Observational studies suggest a benefit with PCI in patients with HF, but randomized data comparing PCI versus medical therapy or PCI versus coronary artery bypass grafting on outcomes and myocardial recovery are lacking. In this interview, Roxana Mehran, MD, FACC; Puja Parikh, MD, MPH, FACC; and Maya Ignaszewski, MD, discuss a recent JACC State-of-the-Art Review on the impact of PCI on outcomes in patients with HF. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Impact of PCI on Outcomes in Patients With HF

The new universal heart failure (HF) definition will be easier for patients and clinicians to understand and will provide standardization across different societies. In this interview, Allen Taylor, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; and Michelle Kelsey, MD, discuss the new definition and stages of HF and their impacts. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Universal Definition of HF Syndrome: Evolving Strategies

Many patients will undergo magnetic resonance imaging (MRI) in their lifetimes. It is important to know that, in most cases, it is possible to perform these scans on patients with a pacemaker as long as appropriate precautions are taken. In this interview, Joseph Marine, MD, MBA, FACC; Andrea Russo, MD, FACC; and Zain Ul Abideen Asad, MD, discuss how to manage the patient with a pacemaker who is undergoing MRI. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Pacemaker Patients Undergoing MRI

In this interview, Kim Williams MD, MACC; John William “Bill” McEvoy, MB, BCh, MHS; and Michelle Kelsey, MD, discuss whether to use aspirin for primary prevention in adults >70 years old with subclinical atherosclerosis. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

ACCEL Lite: Should You “Aspirin” in Older Adults With Subclinical Atherosclerosis?

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by Spencer B. King III, MD, MACC.

hubhopper

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Researc...

hubhopper